Table 2.
Demographic data extracted from the studies comparing the pre-pandemic with the pandemic period.
| No. | Male % | Age * | Stage | Breslow Index (mm) |
|---|---|---|---|---|
| 1 [16] | NR | NR | NR | NR |
| 2 [17] | 58.5% vs. 50.0% | 61 vs. 55 | NR | 0.80 vs. 1.56 |
| 3 [18] | NR | NR | NR | NR |
| 4 [19] | NR | NR | NR | NR |
| 5 [20] | 44.3% vs. 57.5% | 64 vs. 63 | >SI (25.6% vs. 34.3%) | >1 mm (34.1% vs. 44.4%) |
| 6 [21] | 55.8% vs. 43.4% | 77 vs. 53 | SII+SIII (22.1% vs. 55.5%) | 1.08 vs. 2.65 |
| 7 [22] | 55.4% vs. 56.5% | 61 vs. 62 | NR | >1 mm (21.0% vs. 23.0%) |
| 8 [23] | 50.5% vs. 54.4% | 60 vs. 61 | >SII (66.6% vs. 80.0%) | NR |
| 9 [24] | NR | NR | NR | NR |
| 10 [25] | 60.0% | 62 | SIII (38.0%), SIV (62.0%) | NR |
| 11 [26] | NR | NR | NR | NR |
| 12 [27] | 50.8% vs. 50.9% | 60 vs. 59 | NR | 0.40 vs. 0.83 |
| 13 [28] | 62.9% vs. 58.1% | 65.7 vs. 67.0 | SII+SIII (7.1% vs. 27.5%) | NR |
| 14 [29] | NR | NR | NR | 2.06 vs. 2.70 |
| 15 [30] | 48.5% vs. 48.9% | 63 vs. 63 | NR | NR |
| 16 [31] | NR | NR | >TII (2.6% vs. 9.0%) Invasive (13.8% vs. 30.0%) |
0.78 vs. 2.04 |
| 17 [12] | 53.4% vs. 50.7% | 58.1 vs. 58.8 | >SII (58.3% vs. 79.7%) | 1.10 vs. 1.80 |
| 18 [32] | 55.6% vs. 54.5% | NR | NR | NR |
| 19 [33] | NR | NR | NR | NR |
| 20 [34] | NR | NR | NR | 0.88 vs. 1.40 |
| 21 [35] | 57.0% vs. 63.2% | 68.6 vs. 72.6 | >SII (28.9% vs. 32.3%) | NR |
| 22 [11] | NR | NR | NR | NR |
| 23 [36] | 55.8% vs. 57.5% | 68 vs. 68 | >SII (14.5% vs. 15.0%) | 0.87 vs. 1.40 |
| 24 [37] | 52.4% vs. 53.9% | 60.5 vs. 63 | NR | 0.62 vs. 0.70 |
| 25 [38] | 58.9% vs. 57.7% | 67 vs. 68 | >SIIIc (9.9% vs. 10.5%) | NR |
| 26 [39] | 62.7% vs. 52.5% | 61.3 vs. 63.0 | SI (60.8% vs. 54.1%) >SII (5.8% vs. 11.5%) |
49.0% vs. 68.8% > 1 mm |
| 27 [40] | NR | NR | SIV (19% vs. 12% vs. 21%) | 1.70 vs. 1.70 |
| 28 [41] | NR | NR | NR | 0.92 vs. 0.87 |
| 29 [42] | 44.0% vs. 46.4% | 68.5 vs. 75.5 | >SII (56.3% vs. 72.6%) | 1.15 vs. 1.90 |
| 30 [43] | NR | NR | NR | 2.60 vs. 2.90 |
| 31 [44] | NR | NR | >SII (10.0% vs. 22.0%) | 1.60 vs. 2.20 |
| 32 [45] | 51.7% vs. 56.9% | 64.3 vs. 65.4 | >SII (1.5% vs. 2.9%) | NR |
| 33 [46] | NR | NR | SII (14.8% vs. 18.3%) | 1.49 vs. 1.77 |
| 34 [47] | NR | 65.0 vs. 72.0 | SII+SII (31.3% vs. 75.0%) | 0.40 vs. 0.80 |
| 35 [9] | 56.0% vs. 44.0% | 66.2 vs. 63.4 | >SII (18.2% vs. 4.0%) | 6.88 vs. 1.31 |
| 36 [48] | NR | 65 vs. 64 | >SII (7.8% vs. 5.4%) | 0.90 vs. 0.90 |
| 37 [49] | 52.8% vs. 55.7% | 65 vs. 65 | >SII (36.1% vs. 49.2%) | 1.40 vs. 2.00 |
| 38 [50] | NR | 56.2 vs. 57.1 | Invasive (49.4% vs. 56.0%) | 4.70 vs. 4.90 |
| 39 [51] | 41.9% vs. 51.4% | 52.7 vs. 53.3 | >SII (24.8% vs. 42.3%) | 1.00 vs. 1.50 |
* Data reported as mean unless specified differently; NR—not reported; SI—TNM stage 1; SI—TNM stage 2; SIII—TNM stage 3; TNM—Tumor Node Metastasis cancer-staging system.